Kinaset Therapeutics
kinasettherapeutics.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$133M
3 rounds on record
Latest round
$103M
Series B · Jan 2026 · 8 mo ago
Team
3
US Form 5500 (plan participants) · Dec 2025 · 0% in a year
Backers
1
Atlas Venture
The money's age
Fresh money
8 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 29
Board appointment Kinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee Chair · morningstar.com
Jan 10
Raised a round Series B $103M
Jul 5, 2022
Raised a round Venture round $28.5M · SEC Form D
Jul 31, 2020
Raised a round Venture round $1.5M · SEC Form D
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jan 2026 | $103M | — | markets.financialcontent.com |
| Venture round | Jul 2022 | $28.5M | — | SEC Form D |
| Venture round | Jul 2020 | $1.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Kinaset Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Roger HeermanExecutive OfficerSEC Form D
Frazer MorganExecutive OfficerSEC Form D
Robert ClarkeExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Atlas Venture Similar startupsby what they do, their industry and backers
Pulmocide is a biotechnology company developing novel inhaled medicines for pulmonary aspergillosis and other hard-to-treat respiratory…
Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering…
Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation.
Draupnir Bio is developing new innovative therapies for patients.
Diagonal Therapeutics pioneers a new era in medicine by advancing clustering antibody therapeutics targeting the root causes of devastating…
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet…
News
Report
Kinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee Chair - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Kinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee Chair
Read more
Report
EQT Life Sciences backs Kinaset Therapeutics' USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
EQT Life Sciences invests in U.S.-based Kinaset Therapeutics - a clinical-stage biopharma company
Read more
Report
Kinaset Therapeutics: $103 Million Series B Closed To Advance Inhaled Pan-JAK Drug For Severe Asthma
Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases, announced it has closed a $103 million oversubscribed Series B financing to fund mid-stage development of frevecitini
Read more
Report
Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases
Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases
Read more
Report
Kinaset Therapeutics to Share Outcomes from the Phase 1 Clinical Evaluation of Frevecitinib (KN-002), an Inhaled Pan JAK Inhibitor, in Patients with Moderate to Severe Asthma and COPD via Oral Presentations and Poster at ERS Congress
Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced two oral presentations and a late breaking poster
Read more
Report
People
Roger Heerman
Executive Officer
Frazer Morgan
Executive Officer
Robert Clarke
Executive Officer, Director
Jamil Beg
Director
Tom King
Director
Kevin Bitterman
Director
Bram Vanparys
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Medfield
United States
HQ
50-200 est. staff